Novel Therapeutic Perspectives in the Management of DLBCL:
The Role of Antibody-Drug Conjugates and Bispecific Antibodies

Questions marked with a * are required
Contact Information
Credentials/Degree (MD, DO, RN, etc.)
Date of  Participation
Are you a Physician? 
The payload in antibody drug conjugates is:
Which of the following is approved for B-cell lymphoma?
67-year-old woman diagnosed w DLBCL, GCB subtype, not DEL. FISH with MYC rearrangement but without rearrangements of BCL2 or BCL6. Relapsed 1 year after CR w/R-CHOP. Progressed after clinical trial w/IV glofitamab. What would you next recommend?
The most common adverse event in clinical trials evaluating bispecific antibodies was:
Powered by QuestionPro